Absorption, Distribution and Excretion
Accumulation does not occur with repeated dosing.

---

Biological Half-Life
Not Known
...PLASMA HALF-LIFE, 3-5 DAYS...

Protein Binding
Not Known

---

Interactions
Corticotropin and adrenocorticosteroids...reported to cause severe hemorrhage when given with oral anticoagulants...this is rather puzzling, since thrombotic episodes are stated to occur more frequently in pt on steroid therapy, and oral anticoagulants...advised in prophylaxis of such complications. /oral anticoagulants/
Large doses of salicylates have often been assoc with bleeding problems, especially in pt receiving oral anticoagulants. This may be due to direct gastric irritation, suppression of platelet function, or true hypoprothrombinemic effect. ...latter would be antagonized by vitamin K. /oral anticoagulants/
Antimicrobials and other agents that alter intestinal microflora may enhance anti-vitamin K effect of oral anticoagulants, but this is usually not seen unless there is dietary deficiency of vitamin k. /oral anticoagulants/
Thiazide diuretics and ethacrynic acid may enhance effects of oral anticoagulants. /oral anticoagulants/
For more Interactions (Complete) data for ANISINDIONE (21 total), please visit the HSDB record page.

Therapeutic Uses
...Oral anticoagulants are useful in prevention and treatment of variety of thromboembolic disorders. /oral anticoagulants/
...Indications for anticoagulants...myocardial infarction...rheumatic heart Disease...cerebrovascular disease...venous thrombosis and pulmonary embolism, and ...disseminated intravascular coagulation. /oral anticoagulants/
Oral anticoagulants are used to prevent the progression or recurrence of acute deep vein thrombosis or pulmonary embolism following initial course of heparin. They also are effective in preventing venous thromboembolism in patients undergoing orthopedic or gynecological surgery and systemic embolization in patients with acute myocardial infarction, prosthetic heart valves, or chronic atrial fibrillation. /Oral anticoagulants/
Anticoagulants are indicated for prophylaxis and/or treatment of venous (or arterial /Not included in US product labeling/) thrombosis (and its extension) and pulmonary embolism, deep vein thrombosis (DVP) or pulmonary embolism (treatment). Oral anticoagulatns are used during and following initial heparin therapy to decrease the risk of extension, recurrence, or death. /Anticoagulants; Included in US product labeling/
For more Therapeutic Uses (Complete) data for ANISINDIONE (11 total), please visit the HSDB record page.

---

Drug Warnings
Serious, sometimes fatal, toxic reactions were reported occasionally in patients receiving phenindione (no longer commercially available in US), and the possibility of these reactions should be considered in patients receiving anisindione. Adverse effects reported with phenindione (no longer commercially available in US) include dermatologic reactions such as such as urticaria and rash (usually erythematous and macular), which sometimes progressed to exfoliative dermatitis; nephrotic reactions, including anuria and albuminuria with massive edema and tubular necrosis; hepatotoxicity manifested by hepatitis and jaundice; and hematologic reactions manifested by eosinophilia, agranulocytosis or leukopenia (resulting from either maturation arrest or granulocytic hypoplasia), leukocytosis, anemia, thrombecytopenia, atypical mononuclear cells, the presence of leukocyte agglutinins, agranulocytosis, aplastic anemia, and red cell aplasia. In addition, hemorrhagic infarction and necrosis of the skin, alopecia, steatorrhea, sore throat and mouth, parlysis of accommodation and blurred vision, diarrhea, nausea, fever, malaise, and headache have been reported in patients receiving the drug.
In patients with alkaline urine, the urine may be red-orange during therapy with anisindione and patients should be informed of this possibility.
The only consistently reported adverse nonhemorrhagic effect of anisindione is dermatitis. However, agranulocytosis and hepatitis also have been reported with the use of this drug.
Conversely, anisindione (plasma half-life, 3-5 days).../is/ so long-acting that.../it/ may be Hazardous if hemorrhage occurs...
For more Drug Warnings (Complete) data for ANISINDIONE (30 total), please visit the HSDB record page.

---

Pharmacodynamics
Anisindione is a synthetic anticoagulant and an indanedione derivative. It is prescribed only if you cannot take coumarin-type anticoagulants such as coumadin as anisindione is a powerful drug with serious potential side effects. Anticoagulants decrease the clotting ability of the blood and therefore help to prevent harmful clots from forming in the blood vessels. These medicines are sometimes called blood thinners, although they do not actually thin the blood. They also will not dissolve clots that already have formed, but they may prevent the clots from becoming larger and causing more serious problems.

C16H12O3

252.26468

252.079

117-37-3

2197

Pale yellow crystals from acetic acid or ethanol
FINE WHITE TO CREAM-WHITE CRYSTALLINE POWDER

1.263g/cm3

443.9ºC at 760mmHg

155-156
156-157 °C
156.5 °C

199.8ºC

4.45E-08mmHg at 25°C

1.616

2.858

0

3

2

19

344

0

O=C1C(C2=CC=C(OC)C=C2)C(C3=C1C=CC=C3)=O

XRCFXMGQEVUZFC-UHFFFAOYSA-N

InChI=1S/C16H12O3/c1-19-11-8-6-10(7-9-11)14-15(17)12-4-2-3-5-13(12)16(14)18/h2-9,14H,1H3

2-(4-methoxyphenyl)indene-1,3-dione

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

DMSO : ≥ 50 mg/mL (~198.21 mM)

Solubility in Formulation 1: ≥ 2.5 mg/mL (9.91 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

---

Solubility in Formulation 2: ≥ 2.5 mg/mL (9.91 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

---

 (Please use freshly prepared in vivo formulations for optimal results.)